PUBLISHER: Allied Market Research | PRODUCT CODE: 1193051
PUBLISHER: Allied Market Research | PRODUCT CODE: 1193051
The global leukapheresis market was valued at $245.65 million in 2021 and is projected to reach $561.64 million by 2031 registering a CAGR of 8.6% from 2022 to 2031.
Leukapheresis is a laboratory procedure in which white blood cells are removed from a sample of blood. In this process, blood passes through a machine that takes out white blood cells and returns all other blood cells and plasma back into the bloodstream. In addition, the process includes insertion of two intravenous (IV) lines into body. One IV line removes blood while the other carries cleaned blood back to the body. This procedure takes approximately two to three hours to complete.
The growth of global leukapheresis market is majorly driven by increase in demand for leukapheresis, owing to increase in incidences and prevalence of leukemia. In addition, increase in demand for blood donations and rise in demand for leukopaks in clinical research studies responsible for the market growth. Furthermore, increase in awareness regarding leukapheresis procedures in developed countries such as the U.S. further fuel the market growth. However high cost associated with leukapheresis therapeutics and leukopak and blood transfusion safety in developing countries hinder the market growth. Conversely, increase in demand for leukapheresis in pediatric patients is anticipated to provide lucrative opportunities to the market players.
The global leukapheresis market is segmented into product, method, application, end user, and region. By product, the market is categorized into devices and disposables. On the basis of method, it is segregated into centrifugation, membrane separation, and selective adsorption. By application, it is classified into therapeutics application and research application. On the basis of end user, it is categorized into blood centers, hospitals, and others. The others segment further includes research institutes, biopharmaceutical manufacturers, and private medical settings. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key Benefits For Stakeholders
By Product
By Method
By Application
By End User
By Region